Current Developments and Activities on the Safety of Manufactured Nanomaterials (3rd Meeting of the Working Party on Manufactured Nanomaterials held on 28-30 November 2007)
This symposium will be held on 23rd April 2007 in Tokyo, Japan. A two-day OECD WPMN meeting - OECD Workshop on the Sponsorship Programme for the Testing of Manufactured Nanomaterials - will follow this event to discuss the sponsorship programme for the testing of manufactured nanomaterials.
This Programme of Work on Manufactured Nanomaterials 2006-2008 was agreed in September 2006 September by OECD’s Chemicals Committee. To implement this work the Working Party on Manufactured Nanomaterials (WPMN) was established. The Terms of Reference for the WPMN are found in Annex II.
The conference, to be held in Dublin on 2 November 2007, will focus upon the emerging discipline of nanotoxicology and its implications to the broader nanotechnology community. Particular emphasis will be given to the food, environment and medical sectors. The conference will bring together a number of international leaders in the area of nanotoxicology and represents the first conference on this novel topic to be held in Ireland. It
The Royal Society organised a workshop that brought together international academic experts and members of the OECD Working Party on Manufactured Nanomaterials (WPNM). This report summarises the main issues discussed during the workshop.
English, , 2,675kb
This article shows the possible opportunities and risks of nanotechnologies today.
This document provides information on current/planned activities related to the safety of manufactured nanomaterials in OECD countries. Information was provided as written reports by delegations who participated in the 1st Meeting of OECD's Working Party on Manufactured Nanomaterials.
The main objective of the Workshop on the Safety of Manufactured Nanomaterials was to determine the “state-of–the–art” for the safety assessment of manufactured nanomaterials with a particular focus on identifying future needs for risk assessment within a regulatory context.